Roche Holding AG's Fiscal Year is From January To December - All Figures are in CHF, Billions.
The item "End-Period-Cash-Flow" stands at 14.53 Billion Swiss Francs for the trailing twelve months (TTM) period ending 06/30/2025, the highest value since 03/31/2023.'
Regarding the One-Year-Change of the series, the current value constitutes an increase of 42.44 percent compared to the value the year prior.
The 1 year change in percent is 42.44.
The 3 year change in percent is -36.87.
The 5 year change in percent is -32.76.
The 10 year change in percent is 64.04.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - End Period Cash Flow | 905,699,262,464.00 |
![]() | Johnson & Johnson - End Period Cash Flow | 486,508,953,600.00 |
![]() | AbbVie Inc - End Period Cash Flow | 399,570,305,024.00 |
![]() | AstraZeneca PLC - End Period Cash Flow | 280,205,508,085.11 |
![]() | Novartis AG - End Period Cash Flow | 255,096,620,580.91 |